According to the US National Cancer Institute, “a cancer rare cancers as those with an incidence of fewer than 15 cases per 100,000 per year”. It is observed that of all the diagnosed cancers, approximately 22% of the cases are rare cancers. The rare cancer market poses significant challenges in terms of diagnosis and treatment management. Apart from these it also faces unmet needs in terms of rare inadequate knowledge, limited healthcare access, lack of expertise, and high cost of treatment.
To fulfil the unmet need at the therapeutics front, some of the key pharma and biotech companies such as Karyopharm Therapeutics, Deciphera Pharmaceuticals, GSK, BioAtla, Epizyme, Advenchen Laboratories, Adaptimmune, Agios Pharmaceuticals, AstraZeneca, Merck, EMD Serono, QED Therapeutics, Vascular Biogenics Ltd., DNAtrix and many others are diligently working toward the drug development for rare cancers.
For more details, visit: Rare Cancer Treatment Market Trends